Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer

International Journal of Cancer

Volumn 132, Issue 2, 2013, Pages 472-484

  Yokoyama, Takuhei ^a,b   Enomoto, Takayuki ^a   Serada, Satoshi ^b   Morimoto, Akiko ^a,b   Matsuzaki, Shinya ^a,b   Ueda, Yutaka ^a   Yoshino, Kiyoshi ^a   Fujita, Masami ^a   Kyo, Satoru ^c   Iwahori, Kota ^b   Fujimoto, Minoru ^b   Kimura, Tadashi ^a   Naka, Tetsuji ^b  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

BST2; endometrial cancer; iTRAQ; molecular target; plasma membrane

Indexed keywords

ADAM10 ENDOPEPTIDASE; BASAL CELL ADHESION MOLECULE; BONE MARROW STROMAL ANTIGEN 2; BONE MARROW STROMAL ANTIGEN 2 ANTIBODY; CELL MEMBRANE PROTEIN; CELL SURFACE PROTEIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; CUB DOMAIN CONTAINING PROTEIN 1; DESMOGLEIN 2; JUNCTIONAL ADHESION MOLECULE A; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MONOCLONAL ANTIBODY; NERVE CELL ADHESION MOLECULE L1; SYNDECAN 4; TUMOR NECROSIS FACTOR RECEPTOR 5; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTINYLATION; CANCER CELL; CANCER INHIBITION; CANCER TISSUE; CELL MEMBRANE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SCREENING; DRUG TARGETING; ENDOMETRIUM CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MEMBRANE; CYTOTOXICITY, IMMUNOLOGIC; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GPI-LINKED PROTEINS; HUMANS; INJECTIONS, INTRAPERITONEAL; KILLER CELLS, NATURAL; MICE; MICE, INBRED NOD; MICE, SCID; MOLECULAR TARGETED THERAPY; PROTEOME; PROTEOMICS; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869503250     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27679     Document Type: Article

References (48)

1. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-23.
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
3. Leth-Larsen R, Lund RR, Ditzel HJ,. Plasma membrane proteomics and its application in clinical cancer biomarker discovery. Mol Cell Proteomics 2010; 9: 1369-82.
4. Shin BK, Wang H, Yim AM, et al. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem 2003; 278: 7607-16.
5. Zhao Y, Zhang W, Kho Y,. Proteomic analysis of integral plasma membrane proteins. Anal Chem 2004; 76: 1817-23.
6. Ong SE, Blagoev B, Kratchmarova I, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002; 1: 376-86.
7. Alex P, Gucek M, Li X,. Applications of proteomics in the study of inflammatory bowel diseases: current status and future directions with available technologies. Inflamm Bowel Dis 2009; 15: 616-29.
8. Choe L, D'Ascenzo M, Relkin NR, et al. 8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease. Proteomics 2007; 7: 3651-60.
9. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
10. Obel JC, Friberg G, Fleming GF,. Chemotherapy in endometrial cancer. Clin Adv Hematol Oncol 2006; 4: 459-68.
11. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004; 22: 2159-66.
12. Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 2007; 18: 409-20.
13. Kyo S, Nakamura M, Kiyono T, et al. Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. Am J Pathol 2003; 163: 2259-69.
14. Mizumoto Y, Kyo S, Ohno S, et al. Creation of tumorigenic human endometrial epithelial cells with intact chromosomes by introducing defined genetic elements. Oncogene 2006; 25: 5673-82.
15. Scheurer SB, Rybak JN, Roesli C, et al. Identification and relative quantification of membrane proteins by surface biotinylation and two-dimensional peptide mapping. Proteomics 2005; 5: 2718-28.
16. Roden MM, Lee KH, Panelli MC, et al. A novel cytolysis assay using fluorescent labeling and quantitative fluorescent scanning technology. J Immunol Methods 1999; 226: 29-41.
17. Neri S, Mariani E, Meneghetti A, et al. Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin Diagn Lab Immunol 2001; 8: 1131-5.
18. Wang W, Nishioka Y, Ozaki S, et al. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells. Lung Cancer 2009; 63: 23-31.
19. Carter P, Smith L, Ryan M,. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer 2004; 11: 659-87.
20. Mutter GL, Baak JP, Fitzgerald JT, et al. Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol 2001; 83: 177-85.
21. Wong YF, Cheung TH, Lo KW, et al. Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. Oncogene 2007; 26: 1971-82.
22. Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002; 1: 304-13.
23. Tian Q, Stepaniants SB, Mao M, et al. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol Cell Proteomics 2004; 3: 960-9.
24. Mimura K, Kono K, Hanawa M, et al. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 2005; 11: 4898-904.
25. van Meerten T, van Rijn RS, Hol S, et al. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006; 12: 4027-35.
26. Patwardhan AJ, Strittmatter EF, Camp DG II, et al. Comparison of normal and breast cancer cell lines using proteome, genome, and interactome data. J Proteome Res 2005; 4: 1952-60.
27. Tan S, Tan HT, Chung MC,. Membrane proteins and membrane proteomics. Proteomics 2008; 8: 3924-32.
28. Conn EM, Madsen MA, Cravatt BF, et al. Cell surface proteomics identifies molecules functionally linked to tumor cell intravasation. J Biol Chem 2008; 283: 26518-27.
29. Kischel P, Guillonneau F, Dumont B, et al. Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells. Neoplasia 2008; 10: 1014-20.
30. Qiu H, Wang Y,. Quantitative analysis of surface plasma membrane proteins of primary and metastatic melanoma cells. J Proteome Res 2008; 7: 1904-15.
31. Wallin E, von Heijne G,. Genome-wide analysis of integral membrane proteins from eubacterial, archaean, and eukaryotic organisms. Protein Sci 1998; 7: 1029-38.
32. Fogel M, Gutwein P, Mechtersheimer S, et al. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 2003; 362: 869-75.
33. Mamat S, Ikeda J, Enomoto T, et al. Prognostic significance of CUB domain containing protein expression in endometrioid adenocarcinoma. Oncol Rep 2010; 23: 1221-7.
34. Goto T, Kennel SJ, Abe M, et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 1994; 84: 1922-30.
35. Ohtomo T, Sugamata Y, Ozaki Y, et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun 1999; 258: 583-91.
36. Walter-Yohrling J, Cao X, Callahan M, et al. Identification of genes expressed in malignant cells that promote invasion. Cancer Res 2003; 63: 8939-47.
37. Kawai S, Azuma Y, Fujii E, et al. Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Sci 2008; 99: 2461-6.
38. Wang W, Nishioka Y, Ozaki S, et al. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunol Immunother 2009; 58: 967-76.
39. Neil SJ, Zang T, Bieniasz PD,. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451: 425-30.
40. Jouvenet N, Neil SJ, Zhadina M, et al. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 2009; 83: 1837-44.
41. Adams GP, Weiner LM,. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23: 1147-57.
42. Imai K, Takaoka A,. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006; 6: 714-27.
43. Matsuda A, Suzuki Y, Honda G, et al. Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene 2003; 22: 3307-18.
44. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995; 154: 180-91.
45. Mulgrew K, Kinneer K, Yao XT, et al. Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol Cancer Ther 2006; 5: 3122-9.
46. Erikson E, Adam T, Schmidt S, et al. In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/ tetherin in humans. Proc Natl Acad Sci USA 2011; 108: 13688-93.
47. Powles R, Sirohi B, Morgan G, et al. A phase I study of the safety, tolerance, pharmokinetics, antigenicity and efficacy of a single intravenous dose of AHM followed by multiple doses of intravenous AHM in patients with multiple myeloma. Blood 2001; 98: 165A.
48. Tai Y-T, Anderson KC,. Antibody-based therapies in multiple myeloma. Bone Marrow Res 2011; 2011: 924058.